B
SRPT icon

Braidwell’s Sarepta Therapeutics SRPT Stock Holding History

Braidwell’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-832,100
Closed -$16M – 85
2025
Q3 		$16M Buy
+832,100
New +$14.8M 0.48% 51
2025
Q2 		– Sell
-234,500
Closed -$15M – 62
2025
Q1 		$15M Sell
234,500
-130,400
-36% -$13.7M 0.53% 48
2024
Q4 		$44.4M Sell
364,900
-5,500
-1% -$674K 1.32% 30
2024
Q3 		$46.3M Buy
370,400
+288,500
+352% +$39.9M 1.31% 31
2024
Q2 		$12.9M Buy
+81,900
New +$10.5M 0.41% 52
2023
Q1 		– Sell
-140,352
Closed -$18.2M – 96
2022
Q4 		$18.2M Buy
+140,352
New +$16.3M 0.61% 58

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Braidwell's SRPT Position: Q4 2025 in Review

Braidwell sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 832,100 shares — an estimated $16M sold.

Braidwell first reported a position in SRPT in Q4 2022 and held it in 6 quarters. The position peaked at $46.3M in Q3 2024. 347 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Braidwell reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Braidwell sold 832,100 Sarepta Therapeutics shares in Q4 2025, an estimated $16M.
  • Braidwell first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 6 quarters.
  • Braidwell's Sarepta Therapeutics position peaked at $46.3M in Q3 2024.
  • 347 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Braidwell's 13F filing for Q4 2025, filed 17 Feb 2026.